Product Information
NICOTINE 2 MG LOZENGE is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.3468 per EA under NDC 45802034405. Its NADAC has been published 643 times since Jun 11, 2014.
FDA first approved this application on Jan 31, 2006.
Strength
2 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802034405
Classification
Generic
Dosage Form
LOZENGE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NICOTINEApproval Type
Generic (ANDA)
FDA Application
ANDA077007FDA Approved
1/31/2006
On Market Since
3/31/2014
Pharmacological Classes
Price Statistics
The NADAC for NICOTINE 2 MG LOZENGE has been published 643 times since Jun 11, 2014, and over the history we have for it it has declined 7.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3468 per EA |
|---|---|
| All-time high | $0.3959 (Jun 10, 2020) |
| All-time low | $0.2537 (Apr 17, 2024) |
| 52-week high | $0.3504 |
| 52-week low | $0.3242 |
| Median price | $0.3528 |
| Average price | $0.3489 |
| Largest weekly change | +33.9% (Aug 21, 2024) |
| Weeks tracked | 643 |
| Tracking since | Jun 11, 2014 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Nicotine Polacrilex market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Nicotinic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NICOTINE 2 MG LOZENGE?
The current National Average Drug Acquisition Cost (NADAC) for NICOTINE 2 MG LOZENGE, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.3468 per EA (NDC 45802034405), effective Sep 30, 2026.
How has the price of NICOTINE 2 MG LOZENGE changed over time?
Over the history we have for it, the NADAC for NICOTINE 2 MG LOZENGE has declined 7.3%. It has been tracked across 643 weekly CMS publications since Jun 11, 2014.
What are the highest and lowest recorded NADAC prices for NICOTINE 2 MG LOZENGE?
Since Jun 11, 2014, the NADAC for NICOTINE 2 MG LOZENGE has ranged from a low of $0.2537 (Apr 17, 2024) to a high of $0.3959 (Jun 10, 2020), with a median of $0.3528 per EA.
Are there cheaper alternatives to NICOTINE 2 MG LOZENGE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as NICOTINE 2 MG LOZENGE in a comparable dosage form, but none are currently priced below it.
Who manufactures NICOTINE 2 MG LOZENGE?
NICOTINE 2 MG LOZENGE (NDC 45802034405) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.